FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384920166> ?p ?o ?g. }

• W4384920166 abstract "Background Bullous pemphigoid (BP) is a common subepidermal bullous disorder that lacks adequate treatment alternatives. Dupilumab, an anti-interleukin (IL) 4 receptor α antibody blocking Th2 molecules IL-4 and 13, has been used off-label and shown to be effective in refractory BP cases. Methods BP patients with various disease severities and comorbidities were included in this case series. All patients received dupilumab alone or in combination with immunosuppressants in a real-world setting. Complete remission (CR) was defined as the absence of pruritus symptoms and previous BP eruptions, with only hyperpigmentation patches and without newly occurring lesions for at least 4 weeks. Disease relapse was classified as the appearance of three or more new lesions within 1 month or at least one large urticarial or eczematous lesion that did not resolve within a week. Findings Ten individuals were enrolled in this case series. Pruritus symptoms and BP eruptions improved significantly in nine patients (90%). Seven patients (70%) attained CR, including all mild-to-moderate (100%) cases and three of six (50%) severe BP cases. At the dupilumab monotherapy stage, eosinophilia was observed in two severe cases. One patient out of seven (14.3%) relapsed after 1 year of follow-up after CR. Conclusion Treatment of BP with diverse comorbidities with anti-IL-4 receptor α antibody provides further credentials to a prospective randomized study. More impressive efficacy and safety profiles were observed in patients with mild-to-moderate disease after 1 year of follow-up. Eosinophilia may occur in patients receiving dupilumab monotherapy." @default.
• W4384920166 created "2023-07-21" @default.
• W4384920166 creator A5005342849 @default.
• W4384920166 creator A5010870301 @default.
• W4384920166 creator A5012239128 @default.
• W4384920166 creator A5033041205 @default.
• W4384920166 date "2023-07-20" @default.
• W4384920166 modified "2023-10-18" @default.
• W4384920166 title "Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study" @default.
• W4384920166 cites W1684483569 @default.
• W4384920166 cites W1877946602 @default.
• W4384920166 cites W1942788174 @default.
• W4384920166 cites W1954051586 @default.
• W4384920166 cites W1976194277 @default.
• W4384920166 cites W2005401546 @default.
• W4384920166 cites W2012868073 @default.
• W4384920166 cites W2070124869 @default.
• W4384920166 cites W2100866375 @default.
• W4384920166 cites W2161318074 @default.
• W4384920166 cites W2259040952 @default.
• W4384920166 cites W2409152956 @default.
• W4384920166 cites W2464217003 @default.
• W4384920166 cites W2468443869 @default.
• W4384920166 cites W2555773301 @default.
• W4384920166 cites W2588368793 @default.
• W4384920166 cites W2770407202 @default.
• W4384920166 cites W2793854835 @default.
• W4384920166 cites W2803941918 @default.
• W4384920166 cites W2810775394 @default.
• W4384920166 cites W2891235538 @default.
• W4384920166 cites W2901189024 @default.
• W4384920166 cites W2907127795 @default.
• W4384920166 cites W2940005765 @default.
• W4384920166 cites W2946996989 @default.
• W4384920166 cites W2950569641 @default.
• W4384920166 cites W2984751727 @default.
• W4384920166 cites W3010783188 @default.
• W4384920166 cites W3011657961 @default.
• W4384920166 cites W3033599636 @default.
• W4384920166 cites W3038231645 @default.
• W4384920166 cites W3086706932 @default.
• W4384920166 cites W3093342456 @default.
• W4384920166 cites W3129400798 @default.
• W4384920166 cites W3134992772 @default.
• W4384920166 cites W3135345261 @default.
• W4384920166 cites W3207627503 @default.
• W4384920166 cites W3209567618 @default.
• W4384920166 cites W3215901680 @default.
• W4384920166 cites W4210471363 @default.
• W4384920166 cites W4211074864 @default.
• W4384920166 cites W4224983978 @default.
• W4384920166 cites W4225407703 @default.
• W4384920166 cites W4280517787 @default.
• W4384920166 cites W4280580397 @default.
• W4384920166 cites W4281764736 @default.
• W4384920166 cites W4283067571 @default.
• W4384920166 cites W4286499983 @default.
• W4384920166 cites W4296893285 @default.
• W4384920166 cites W4298326572 @default.
• W4384920166 cites W4304116195 @default.
• W4384920166 cites W4307035074 @default.
• W4384920166 cites W4308686079 @default.
• W4384920166 cites W4313237193 @default.
• W4384920166 doi "https://doi.org/10.3389/fimmu.2023.1165106" @default.
• W4384920166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37545503" @default.
• W4384920166 hasPublicationYear "2023" @default.
• W4384920166 type Work @default.
• W4384920166 citedByCount "0" @default.
• W4384920166 crossrefType "journal-article" @default.
• W4384920166 hasAuthorship W4384920166A5005342849 @default.
• W4384920166 hasAuthorship W4384920166A5010870301 @default.
• W4384920166 hasAuthorship W4384920166A5012239128 @default.
• W4384920166 hasAuthorship W4384920166A5033041205 @default.
• W4384920166 hasBestOaLocation W43849201661 @default.
• W4384920166 hasConcept C11988809 @default.
• W4384920166 hasConcept C121332964 @default.
• W4384920166 hasConcept C126322002 @default.
• W4384920166 hasConcept C142424586 @default.
• W4384920166 hasConcept C159654299 @default.
• W4384920166 hasConcept C16005928 @default.
• W4384920166 hasConcept C200155923 @default.
• W4384920166 hasConcept C203014093 @default.
• W4384920166 hasConcept C2777129736 @default.
• W4384920166 hasConcept C2778075117 @default.
• W4384920166 hasConcept C2778329239 @default.
• W4384920166 hasConcept C2778690821 @default.
• W4384920166 hasConcept C2779252107 @default.
• W4384920166 hasConcept C2779824493 @default.
• W4384920166 hasConcept C71924100 @default.
• W4384920166 hasConcept C87355193 @default.
• W4384920166 hasConcept C90924648 @default.
• W4384920166 hasConceptScore W4384920166C11988809 @default.
• W4384920166 hasConceptScore W4384920166C121332964 @default.
• W4384920166 hasConceptScore W4384920166C126322002 @default.
• W4384920166 hasConceptScore W4384920166C142424586 @default.
• W4384920166 hasConceptScore W4384920166C159654299 @default.
• W4384920166 hasConceptScore W4384920166C16005928 @default.
• W4384920166 hasConceptScore W4384920166C200155923 @default.
• W4384920166 hasConceptScore W4384920166C203014093 @default.
• W4384920166 hasConceptScore W4384920166C2777129736 @default.

• next